BioLife Solutions (NASDAQ:BLFS) Rating Lowered to “Hold” at Maxim Group

BioLife Solutions (NASDAQ:BLFS) was downgraded by equities researchers at Maxim Group from a “strong-buy” rating to a “hold” rating in a report released on Wednesday,Zacks.com reports.

BLFS has been the topic of a number of other research reports. Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 12th. William Blair set a $31.00 price objective on shares of BioLife Solutions in a report on Thursday. Craig Hallum lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a research report on Wednesday. Lake Street Capital cut shares of BioLife Solutions from a “buy” rating to a “hold” rating and cut their target price for the stock from $33.00 to $31.00 in a research note on Wednesday. Finally, HC Wainwright downgraded shares of BioLife Solutions from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $32.00 to $31.00 in a report on Thursday. One investment analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $31.43.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $30.77 on Wednesday. The stock has a 50-day simple moving average of $26.76 and a 200 day simple moving average of $23.50. The stock has a market capitalization of $1.50 billion, a P/E ratio of -384.58 and a beta of 1.94. BioLife Solutions has a 52 week low of $17.86 and a 52 week high of $32.23.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. BioLife Solutions had a positive return on equity of 1.81% and a negative net margin of 2.80%.The firm had revenue of $27.50 million for the quarter, compared to analyst estimates of $25.66 million. Research analysts forecast that BioLife Solutions will post 0.02 earnings per share for the current year.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $23.70, for a total value of $15,405,000.00. Following the transaction, the insider directly owned 4,757,165 shares of the company’s stock, valued at $112,744,810.50. This represents a 12.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 1,200,000 shares of company stock valued at $28,125,000. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors and hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company lifted its position in BioLife Solutions by 2.7% during the second quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock worth $447,000 after purchasing an additional 555 shares during the period. Isthmus Partners LLC increased its holdings in BioLife Solutions by 0.5% in the 4th quarter. Isthmus Partners LLC now owns 138,393 shares of the medical equipment provider’s stock valued at $3,346,000 after buying an additional 622 shares during the period. Thrivent Financial for Lutherans raised its position in shares of BioLife Solutions by 2.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 27,278 shares of the medical equipment provider’s stock valued at $588,000 after buying an additional 702 shares in the last quarter. Quarry LP lifted its holdings in shares of BioLife Solutions by 50.9% during the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after acquiring an additional 713 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of BioLife Solutions by 2.9% during the 3rd quarter. Millennium Management LLC now owns 27,698 shares of the medical equipment provider’s stock worth $707,000 after acquiring an additional 783 shares during the period. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Key BioLife Solutions News

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: BioLife’s pending acquisition by Repligen underscores strategic value in its cell-therapy and biopreservation business, with analysts noting potential revenue and EPS benefits from the deal. Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
• Neutral Sentiment: HC Wainwright reiterated a Neutral view and a $31 price target while publishing 2027 earnings estimates of $0.03-$0.05 per share, suggesting modest longer-term profitability expectations. BioLife Solutions analyst estimates
• Neutral Sentiment: HC Wainwright’s quarterly estimates indicate expected earnings improvement into 2027, but the forecasts are not materially above the current valuation narrative. BioLife Solutions analyst estimates
• Negative Sentiment: Maxim Group downgraded BioLife Solutions from Strong Buy to Hold, a sign that enthusiasm for the shares is fading after the recent run-up. Maxim Group downgrade
• Negative Sentiment: TD Cowen also cut BioLife to Hold, adding to the cautious analyst tone around the stock. TD Cowen downgrade
• Negative Sentiment: Investigation headlines from multiple law firms over whether BioLife shareholders are receiving a fair price in the Repligen deal are creating uncertainty around the transaction. Shareholder investigation

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.